DelveInsight’s “BRAF-Mutant Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the BRAF-Mutant Metastatic Melanoma, historical and forecasted epidemiology as well as the BRAF-Mutant Metastatic Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The BRAF-Mutant Metastatic Melanoma market report provides current treatment practices, emerging drugs, BRAF-Mutant Metastatic Melanoma market share of the individual therapies, current and forecasted BRAF-Mutant Metastatic Melanoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current BRAF-Mutant Metastatic Melanoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the BRAF-Mutant Metastatic Melanoma market.
Some of the key facts of the BRAF-Mutant Metastatic Melanoma Market Report:
-
As per Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new melanoma skin cancer cases in the UK every year. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.
-
As per the National Organization for Rare Disorders 2020, the incidence of these types of skin cancers is increasing at a relatively fast rate as compared with other forms of cancer. The risk of melanoma is higher in people of European descent than in other populations.
-
A darker pigmentation to the skin may be associated with a lower risk of Metastatic Melanoma. It is also associated with a greater risk for those individuals with blue eyes and a fair complexion.
Got queries? Click here to know more about the BRAF-Mutant Metastatic Melanoma Market Landscape
BRAF-Mutant Metastatic Melanoma Overview
Melanoma is a common skin cancer that arises from the melanin cells within the upper layer of the skin (epidermis) or from similar cells that may be found in moles (nevi). This type of skin cancer may send down roots into deeper layers of the skin, and some of these microscopic roots may spread (metastasize), causing new tumor growths in vital organs of the body.
The most prevalent driver in melanoma is mutant BRAF, found in 40–50% of patients with metastatic disease. BRAF mutations occur in other cancers such as colon cancer, papillary thyroid cancer, and serous ovarian cancer, but at a frequency much lower than in melanoma.
Most severe complications include secondary infection; lymphedema; local; metastases; and anxiety.
Several unmet needs are associated with melanoma, such as the need for prognostic biomarkers, raising awareness, better clinical research, monitoring toxicity of immune checkpoint inhibitors, and the need for neoadjuvant therapy.
Despite the initial response observed in most patients treated with targeted therapy, acquired resistance is almost inevitable and occurs in approximately half of all patients within the first year of therapy.
BRAF-Mutant Metastatic Melanoma Market Epidemiological Insights:
-
Melanoma of the skin represents 5.6% of all new cancer cases in the U.S., with the rate of new cases of melanoma of the skin being 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.
-
According to The Cancer Genome Atlas Network., the BRAF mutation occurs in approximately 50% of cutaneous melanoma and the most common being the V600E (valine to glutamic acid; 70–88%).
-
According to Cancer.Net, if the melanoma has spread to other, distant parts of the body, the survival rate is lower, about 27%. Approximately 4% of cases are diagnosed at this stage.
-
According to the Study conducted by Jose et. at. (2020), around 42% of patients with stage IIIc and IV melanoma carried BRAF mutations in Spain.
BRAF-Mutant Metastatic Melanoma Market Epidemiological Segmentation
-
Total BRAF Metastatic Melanoma type-specific cases
-
Total BRAF Metastatic Melanoma stage-specific cases
-
Total BRAF Metastatic Melanoma treated cases
-
Total BRAF Metastatic Melanoma age-specific cases
-
Total BRAF Metastatic Melanoma mutation-specific cases
BRAF-Mutant Metastatic Melanoma Market Outlook
The BRAF-Mutant Metastatic Melanoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted BRAF-Mutant Metastatic Melanoma market trends by analyzing the impact of current BRAF-Mutant Metastatic Melanoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the BRAF-Mutant Metastatic Melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated BRAF-Mutant Metastatic Melanoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the BRAF-Mutant Metastatic Melanoma market in 7MM is expected to witness a major change in the study period 2019-2032.
BRAF-Mutant Metastatic Melanoma Key Companies
-
Merck Sharp & Dohme
-
Regeneron Pharmaceuticals
-
Iovance Biotherapeutics
-
Highlight Therapeutics
-
And many more
BRAF-Mutant Metastatic Melanoma Therapies
-
LENVIMA
-
vidutolimod
-
LIFILEUCEL
-
BO-112 with Pembrolizumab
-
And many more
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of BRAF-Mutant Metastatic Melanoma
-
Disease Background and Overview
-
Epidemiology and patient population
-
The United States
-
EU 5
-
BRAF-Mutant Metastatic Melanoma Emerging Therapies
-
BRAF-Mutant Metastatic Melanoma Market Outlook
-
Market Access and Reimbursement of Therapies
-
Appendix
-
BRAF-Mutant Metastatic Melanoma Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Click here to read more about BRAF-Mutant Metastatic Melanoma Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/